Getting the Right Evidence After Drug Approval

To generate comparative evidence in a timely fashion for drugs without restricting or delaying access, value-based pricing and reimbursement could be conditioned on a prospective, post-approval evidence generation plan.

Detalles Bibliográficos
Autores principales: Vreman, Rick A., Leufkens, Hubert G. M., Kesselheim, Aaron S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509198/
https://www.ncbi.nlm.nih.gov/pubmed/33013409
http://dx.doi.org/10.3389/fphar.2020.569535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509198/
https://www.ncbi.nlm.nih.gov/pubmed/33013409
http://dx.doi.org/10.3389/fphar.2020.569535

Ejemplares similares